Clicky

Allergy Therapeutics Plc(AGY)

Description: Allergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company's segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World. The Company provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy. The Company's products include Pollinex Trees, Pollinex Grasses+Rye, Skin Prick Testing and diagnostic products. Its vaccines trade under various brand names, such as Pollinex Quattro, Polligoid and TA Graser Top. It uses specialized systems to process the Tyrosine to form a suspension microcrystalline tyrosine (MCT) that is combined with some of its subcutaneous injected therapies.


Keywords: Medicine Pharmaceutical Pain Immunology Immune System Immunotherapy Allergy Vaccination Diagnostic Products Skin Testing Allergology Therapies Allergen Immunotherapy Alk Abelló Hal Allergy Group Allergy Therapeutics Desensitization

Home Page: www.allergytherapeutics.com

AGY Technical Analysis

Dominion Way
Worthing, BN14 8SA
United Kingdom
Phone: 44 1903 844 700


Officers

Name Title
Mr. Manuel Llobet CEO & Exec. Director
Mr. Martin Hopcroft Interim Chief Financial Officer
Ms. Beverly Lees Group Operations Director
Dr. Murray Skinner Chief Scientific Officer
Mr. Santiago Puig Bus. Devel. Director
Ms. Sue Baker Head of HR
Simon Piggott Head of Clinical Science
Alan Bullimore Head of Communication & Market Devel.
Mr. Russell Picket Group Financial Controller
Sara Goldsbrough Company Sec.

Exchange: LSE

Country: UK

Currency: Pence sterling (p)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 2.0782
Price-to-Sales TTM: 1.0849
IPO Date:
Fiscal Year End: June
Full Time Employees: 600
Back to stocks